These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 7594611)
1. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611 [TBL] [Abstract][Full Text] [Related]
2. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600 [TBL] [Abstract][Full Text] [Related]
4. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176 [TBL] [Abstract][Full Text] [Related]
6. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420 [TBL] [Abstract][Full Text] [Related]
8. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829 [TBL] [Abstract][Full Text] [Related]
9. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050 [TBL] [Abstract][Full Text] [Related]
10. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes. Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164 [TBL] [Abstract][Full Text] [Related]
11. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379 [TBL] [Abstract][Full Text] [Related]
12. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. Darrow TL; Slingluff CL; Seigler HF J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621 [TBL] [Abstract][Full Text] [Related]
14. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes. Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087 [TBL] [Abstract][Full Text] [Related]
15. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580 [TBL] [Abstract][Full Text] [Related]
17. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040 [TBL] [Abstract][Full Text] [Related]
18. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166 [TBL] [Abstract][Full Text] [Related]
19. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892 [TBL] [Abstract][Full Text] [Related]
20. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]